Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01683175

Recruitment Status : Unknown

Verified October 2016 by Tianjin Medical University Cancer Institute and Hospital.
Recruitment status was: Active, not recruiting

First Posted : September 11, 2012

Last Update Posted : October 20, 2016

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Roche Pharma AG

Information provided by (Responsible Party):

Tianjin Medical University Cancer Institute and Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	October 2020
Estimated Study Completion Date :	October 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Wang C. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.

To Top